Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 767-770

  Beltinger, Johannes ^a   Haschke, Manuel ^a   Kaufmann, Priska ^a   Michot, Marc ^a   Terracciano, Luigi ^a   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Apoptosis; Cyclophosphamide; Drug drug interaction; Roxithromycin

Indexed keywords

ANTICOAGULANT AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; ENALAPRIL; GLYCOPROTEIN P; INSULIN; PHENPROCOUMON; PREDNISONE; ROXITHROMYCIN;

AGED; APOPTOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPNEA; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER VENOOCCLUSIVE DISEASE; LUNG EMBOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; TREATMENT OUTCOME;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; CYCLOPHOSPHAMIDE; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ROXITHROMYCIN;

EID: 33646266274     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G441     Document Type: Article

References (13)

1. Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003;32:969-78.
2. MacQuillan OC, Mutimer D. Fulminant liver failure due to severe venoocclusive disease after haematopoietic cell transplantation: a depressing experience. QJM 2004;97:581-9.
3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
4. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61:443-98.
5. Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 1998;26:1053-7.
6. Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996;51:297-301.
7. Blomgren H, Hallstrom M. Possible role of acrolein in 4-hydroperoxycyclophosphamide-induced cell damage in vitro. Methods Find Exp Clin Pharmacol 1991;13:ll-4.
8. Kimura Y, Matsuo M, Takahashi K, et al. ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein. Curr Drug Metab 2004;5:1-10.
9. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001;31:469-97.
10. Kamath AV, Morris ME. Functional expression of P-glycoprotein in the hepatic canalicular membrane of developing rats. J Pharm Sci 1998;87:785-6.
11. LeBlanc GA. Hepatic vectorial transport of xenobiotics. Chem Biol Interact 1994;90:101-20.
12. Hamano Y, Sugimoto H, Soubasakos MA, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64:1570-4.
13. Villa P, Sassella D, Corada M, Bartosek I. Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base. Antimicrob Agents Chemother 1988;32:1541-6.